WSJ Tech News Briefing · Friday, September 25, 2026
Novo Nordisk has entered into a significant agreement with Nexe to license and develop the latter's drug delivery technology. This deal, potentially worth up to $1.3 billion, aims to reduce the frequency of injections for patients receiving obesity and diabetes medications. The technology involves coating drug particles to enable a controlled, sustained release.
“Novo Nordisk agreed to pay up to $1.3 billion to license and develop Nexe's drug delivery technology.”
“The exclusive deal covers Nexe's pharmaceutical technology, which could cut the frequency that patients need to inject obesity and diabetes drugs.”
“The technology applies an ultra-thin coating to drug particles for controlled sustained release.”